Safety, Functional Disability, Healthcare Utilization, and Quality-of-Life Outcomes in Elderly Receiving Alteplase and Tenecteplase: A Secondary Analysis From the AcT Trial.
Singh N, Bala F, Ademola A, Almekhlafi M, Coutts SB, Deschaintre Y, Khosravani H, Buck BH, Appireddy R, Moreau F, Gubitz G, Tkach A, Catanese L, Dowlatshahi D, Medvedev G, Mandzia J, Pikula A, Shankar JJ, Poppe AY, Williams H, Field TS, Manosalva A, Siddiqui M, Zafar A, Imoukhoude O, Hunter G, Shamy M, Demchuk A, Swartz RH, Hill MD, Sajobi TT, Menon BK, Ganesh A.
Singh N, et al.
Stroke. 2025 May;56(5):1169-1179. doi: 10.1161/STROKEAHA.124.049512. Epub 2025 Mar 24.
Stroke. 2025.
PMID: 40123483
Clinical Trial.
Outcomes included functional disability (per 90-day modified Rankin Scale), safety (24-hour symptomatic intracerebral hemorrhage, 90-day mortality rates), health care utilization (discharge destination, length of stay, thrombectomy rate), and quality of life measures (EQ-5D …
Outcomes included functional disability (per 90-day modified Rankin Scale), safety (24-hour symptomatic intracerebral hemorrhage, 90-day mor …